BioNTech (NASDAQ:BNTX) CEO Sells 30,000 Shares

BioNTech SE Sponsored ADR (NASDAQ:BNTX) CEO Ugur Sahin sold 30,000 shares of the business’s stock in a transaction dated Friday, September 18th. The stock was sold at an average price of $96.22, for a total value of $2,886,600.00. Following the sale, the chief executive officer owned 489,209 shares in the company, valued at approximately $47,071,689.98. This trade represents a 5.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ugur Sahin also recently made the following trade(s):

• On Thursday, September 17th, Ugur Sahin sold 34,000 shares of BioNTech stock. The shares were sold at an average price of $98.60, for a total transaction of $3,352,400.00.
• On Wednesday, September 16th, Ugur Sahin sold 15,000 shares of BioNTech stock. The stock was sold at an average price of $96.09, for a total transaction of $1,441,350.00.
• On Tuesday, September 15th, Ugur Sahin sold 34,000 shares of BioNTech stock. The stock was sold at an average price of $96.49, for a total transaction of $3,280,660.00.
• On Monday, September 14th, Ugur Sahin sold 41,000 shares of BioNTech stock. The shares were sold at an average price of $99.45, for a total transaction of $4,077,450.00.
• On Friday, September 11th, Ugur Sahin sold 45,000 shares of BioNTech stock. The shares were sold at an average price of $96.93, for a total transaction of $4,361,850.00.
• On Thursday, September 10th, Ugur Sahin sold 20,500 shares of BioNTech stock. The stock was sold at an average price of $96.31, for a total transaction of $1,974,355.00.
• On Wednesday, September 9th, Ugur Sahin sold 36,000 shares of BioNTech stock. The stock was sold at an average price of $97.78, for a total transaction of $3,520,080.00.
• On Tuesday, September 8th, Ugur Sahin sold 37,000 shares of BioNTech stock. The stock was sold at an average price of $99.20, for a total transaction of $3,670,400.00.
• On Friday, September 4th, Ugur Sahin sold 31,500 shares of BioNTech stock. The shares were sold at an average price of $103.52, for a total value of $3,260,880.00.
• On Thursday, September 3rd, Ugur Sahin sold 45,000 shares of BioNTech stock. The stock was sold at an average price of $102.85, for a total value of $4,628,250.00.

BioNTech Trading Down 2.6%

NASDAQ:BNTX traded down $2.60 during trading hours on Friday, hitting $96.06. 1,150,292 shares of the company were exchanged, compared to its average volume of 1,102,362. The stock has a market capitalization of $24.29 billion, a price-to-earnings ratio of -12.27 and a beta of 1.29. BioNTech SE Sponsored ADR has a one year low of $79.52 and a one year high of $124.00. The company has a fifty day simple moving average of $97.29 and a 200 day simple moving average of $94.92. The company has a current ratio of 7.85, a quick ratio of 7.80 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by ($0.13). BioNTech had a negative net margin of 63.54% and a negative return on equity of 6.86%. The company had revenue of $122.31 million during the quarter, compared to analyst estimates of $180.18 million. During the same period in the previous year, the company posted ($1.60) EPS. The company’s quarterly revenue was down 59.5% on a year-over-year basis. Sell-side analysts expect that BioNTech SE Sponsored ADR will post -6.33 EPS for the current fiscal year.

Hedge Funds Weigh In On BioNTech

A number of institutional investors and hedge funds have recently modified their holdings of BNTX. Engineers Gate Manager LP increased its stake in shares of BioNTech by 17.3% in the 2nd quarter. Engineers Gate Manager LP now owns 12,433 shares of the company’s stock valued at $1,157,000 after acquiring an additional 1,833 shares in the last quarter. Integrated Wealth Concepts LLC bought a new position in BioNTech during the second quarter worth $39,000. Nykredit A S bought a new position in BioNTech during the second quarter worth $293,000. B. Metzler seel. Sohn & Co. AG grew its holdings in BioNTech by 66.7% in the second quarter. B. Metzler seel. Sohn & Co. AG now owns 10,967 shares of the company’s stock worth $1,020,000 after purchasing an additional 4,390 shares during the period. Finally, Headlands Technologies LLC acquired a new stake in BioNTech in the second quarter worth $2,520,000. 15.52% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on BNTX shares. Jefferies Financial Group restated a “buy” rating on shares of BioNTech in a research report on Monday, June 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a research report on Monday, July 6th. Wall Street Zen downgraded shares of BioNTech from a “hold” rating to a “sell” rating in a research note on Saturday, August 8th. Sanford C. Bernstein restated a “market perform” rating on shares of BioNTech in a report on Friday, June 5th. Finally, Canaccord Genuity Group cut their price target on shares of BioNTech from $142.00 to $136.00 and set a “buy” rating on the stock in a research report on Monday, August 31st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $126.00.

About BioNTech

BioNTech SE is a biotechnology company focused on developing immunotherapies and vaccines for cancer and other serious diseases. Its research platforms include messenger RNA, cell therapies, protein-based therapeutics, antibody therapies and small-molecule immunomodulators.

The company is best known for Comirnaty, its COVID-19 vaccine developed and commercialized globally in collaboration with Pfizer. BioNTech is also advancing a broad oncology pipeline that includes individualized and off-the-shelf cancer vaccines, antibody-based treatments, cell therapies and combination approaches designed to stimulate or direct the immune system against tumors.

BioNTech was founded in 2008 and is headquartered in Mainz, Germany.